http://www.broadinjectables.in/

Broad Injectables, Una (2026)

26/12/2018

Delhi High Court Stays Online Sale Of Drugs, Prescribed Medicines

The Delhi High Court has stayed the sale of drugs and prescribed medicines by online pharmacies.
A bench of Chief Justice Rajendra Menon and Justice VK Rao has passed the interim order on a plea seeking a ban on "illegal" sale of drugs and medicines online.

Advocate Nakul Mohta, appearing for the petitioner, said, "As an interim measure, the court has stopped unauthorised sale of medicines on the Internet and the government has been asked to take necessary steps forthwith."

The court had earlier sought responses of the centre, Delhi government, Central Drugs Standard Control Organisation, Pharmacy Council of India on the petition.

The court has listed the matter for further hearing on March 25 next year.

The petition filed by Zaheer Ahmed said the online illegal sale of medicines would lead to a drug epidemic, drug abuse and mis-utilisation of habit forming and addictive drugs.

It claimed that the Ministry of Health and Family Welfare, Central Drugs Standard Control Organisation and an expert committee appointed by the drug consultative committee have already concluded that the online sale of medicines is in contravention of the provisions of Drugs and Cosmetics Act, 1940 and the other allied laws.

Still lakhs of drugs are being sold on internet every day, it said, adding that some of the drugs/ medicines contain narcotic and psychotropic and some can cause antibiotic resistant-bacteria which is a threat not only to the patient but to the humanity at large.

"It is a matter of public knowledge that e-commerce websites have been caught on numerous occasions of selling fake products. Unlike consumer items, drugs are extremely potent substances and consuming wrong dose or fake medicine can have fatal consequences on the patient," it said.

The petition said that as of now there is no mechanism to control the sale of medicines on the Internet and this puts the health and life of people at a high risk and affects their right to a safe and healthy life under Article 21 of the Constitution.

A large number of children use the Internet and they could be victims of wrong medications, it added.

"Online pharmacies are operating without a drug licence and cannot be regulated in the present regime. Unregulated and unlicensed sale of medicines will increase risk of spurious, misbranded and sub-standard drugs being sold," the plea said.

It claimed that the online pharmacies are selling prescription medicines in large numbers without a valid prescription which was a dangerous trend.

The plea has sought direction to the authorities to take action against the entities distributing, selling or exhibiting drugs on the internet.

24/12/2018

No Online Sale Of Medicines Till Regulation In Place, Says High Court

The Delhi High Court on Tuesday said its stay on sale of drugs and prescription medicines by online pharmacies will continue till rules are framed to regulate such entities.
A bench of Chief Justice Rajendra Menon and Justice VK Rao said that "once the rules come into play, you (online pharmacies) can start selling it (medicines). Problem is that today there are no rules regulating it".

The observations by the bench were made while hearing the applications moved by some online pharmacies seeking to be impleaded in the matter.

The pharmacies urged the court to remove the prohibition on online sale of drugs, saying they held licences and no medicines were sold illegally.

They also contended that even prescription drugs were sold only if there was a valid prescription from a doctor.

The applications for impleadment were filed in a petition by Zaheer Ahmed seeking a ban on "illegal" sale of drugs and medicines online.

During the hearing, the petitioner informed the bench that the Madras High Court on Monday had banned online sale of medicines till the Union Health Ministry and the Central Drugs Standard Control Organisation (CDSCO) notified the proposed Drugs and Cosmetics Amendment Rules, 2018 in the gazette at the earliest by January 31.

The Madras High Court, however, directed the authorities concerned not to give effect to the order till December 20 in order to enable online pharmacies to challenge the decision.

On being informed of the development, the Delhi High Court listed the matter for hearing on December 20.

In his petition, Mr Ahmed said that the online illegal sale of medicines would lead to a drug epidemic, drug abuse and mis-utilisation of habit forming and addictive drugs.

It has claimed that the Ministry of Health, CDSCO and an expert committee appointed by the drug consultative committee have already concluded that the online sale of medicines was in contravention of the provisions of Drugs and Cosmetics Act, 1940 and the other allied laws.

Still lakhs of drugs are being sold on the Internet every day, it has said, adding that some of the drugs and medicines contain narcotic and psychotropic substance and some can cause antibiotic resistant-bacteria which is a threat not only to the patient but to the humanity at large.

"It is a matter of public knowledge that e-commerce websites have been caught on numerous occasions of selling fake products. Unlike consumer items, drugs are extremely potent substances and consuming wrong dose or fake medicine can have fatal consequences on the patient," it said.

The petition said that as of now there is no mechanism to control the sale of medicines on the Internet and this puts health and lives of people at a high risk and affects their right to a safe and healthy life under Article 21 of the Constitution.

"Online pharmacies are operating without a drug licence and cannot be regulated in the present regime. Unregulated and unlicensed sale of medicines will increase risk of spurious, misbranded and sub-standard drugs being sold," the plea has said.

The plea has sought direction to the authorities to take action against the entities distributing, selling or exhibiting drugs on the internet.

10/12/2018

ADVANTAGES OF THIRD PARTY MANUFACTURING IN PHARMA INDUSTRY
Third party manufacturing of pharmaceutical business has been a widely used, popular business model from quite some time. It is also referred to as contract manufacturing.

You will be wondered to know that amongst the pharmaceutical products sold today, the majority are third-party products.

The fundamental concept of this model is to the production of drugs by a pharmaceutical company under the name or brand of another company.

The company which outsources the production work keeps the responsibility of publicizing and promoting the products and brand.

This business model became popular because it gives an excellent business opportunity to both parties.

BENEFITS OF MANUFACTURING PHARMA PRODUCTS UNDER THE THIRD-PARTY MODEL

Why is this model getting such an enormous appeal? Here are some unique advantages.

Third-party manufacturers give support to multiple clients (notwithstanding competing) as per the recipes and outline provided by them.
The pharma company gets quality products if a reliable and experienced third-party manufacturer is selected.
Business expansion with low investment is possible using this model. It is easy to add one more product to the product line without increasing the investment much. If the third-party manufacturer uses standardized production setup, then expansion becomes furthermore easy.
Both product company and third-party manufacturer get the advantages. A third-party manufacturer can produce the similar product for different companies with different brand names. Similarly, a pharma company can outsource the same drug to different manufacturers. Thus, high levels of business efficiency can be achieved.
Cost-effectiveness is the apparent business benefit. The services offered by third-party manufacturers are less costly than managing in-house. The pharma company gets relieved from the worries of arranging the starting capital and recurring maintenance costs.
When the products are in high demand, the third-party production becomes highly cost-effective. The product owner can negotiate on better prices based on bulk production. The third-party manufacturer will fulfill the additional requirement at concessional rates as it will increase their profitability as well.
After outsourcing the production process to a third-party manufacturer, the pharma company gets an uninterrupted supply of quality drugs. The professionalism and expertise of both partners raise the bar higher and higher. The long professional experience of both helps in getting more business.
In short, the benefits of manufacturing pharma products using the third-party model are many. Finding an experienced, reputable third-party partner is a challenging task. It requires a lot of study and research.

Once you get a good partner, the rest of the things become easy.

10/12/2018

Softgel Manufacturing India

Softgel Manufacturing in India is today a booming market. With limited players in the industry, soft gelatin capsule manufacturing in India offers wide domestic market as well as opportunities to export soft gelatin capsules world-wide. At present Broad Injectables, its pharmaceutical formulations in soft gelatin capsule form in more than 15 countries spread in all the continents of the world. WHO GMP Certified manufacturing facilities for soft gelatin capsules alongside other dosage forms is a state of the art , India which offers best quality pharmaceutical formulations in best time line. We offer a very large manufacturing capacity in soft gelatin capsules formulations for exports in regulated as well as non-regulated markets.

Some of the major therapeutic segments covered by our softgel formulations are: cardiac, diabetic, nutritional supplements, vitamin supplement, minerals, anti-oxidants, anti-inflammatory, anti-biotics, anti-bacterial, anti-fungals etc.

10/12/2018

What is the Scope of Pharmacy in India?

FUTURE OF PHARMACY BUSINESS IN INDIA
India has shown significant growth in the last few decades. It is one of the strongest economies in the world today.

Though every sector has performed well, industries such as pharmacy have grown remarkably well.

Not only entrepreneurs but people aspiring for making a bright career in pharmacy also find it lucrative.

Experts say that in the coming years, pharmacy business will become more profitable. Hence, it is a wise thing to start early.

As far as various business prospects are concerned, one can excel in the niche by working sincerely. Here are a few areas that show a promising future.

RESEARCH AND DEVELOPMENT
Research and development or R&D are the core of pharma business. According to the business analysts, there will be a high demand for qualified pharmacists.

Resources that possess higher degrees such as M. Pharma or Ph.D. will get priority.

Research on new drugs
Process development
Formulation
Development
Clinical trials
Toxicological studies
Formulation and development
ANALYSIS AND TESTING
Analysis and testing go together. For this pharma companies require highly skilled people. They can take care of analytical work and sophisticated equipment.

Quality Control or QC, and Quality Assurance or QA are areas where a lot of job opportunities will generate in the coming times.

These job profiles are important in a pharma business, and highly respectable and rewarding as well.

MANUFACTURING
As the demand for medicines increases, new industries are coming up. To manage production and operation in these industries, entrepreneurs need qualified people.

In a production industry, various skills are required. Starting from production to operation, and maintenance to quality control; the need for human resources is everywhere.

SALES AND MARKETING
It is not enough to manufacture pharmaceutical products in manufacturing units. It is equally important to take them to the customers.

Sales and marketing teams play a vital role in it. They explore the markets and find out areas with high business potential.

People who have a good caliber of convincing others can make a bright career in sales and marketing of pharmaceutical products.

CAREER IN HOSPITALS
The pharmacists work in hospitals are people who know better about the drugs prescribed there Though it is a more familiar thing in the western countries, in India also hospitals are appointing qualified pharmacists nowadays.

Since it is a flourishing niche, it is a wise decision to launch pharmacy business today. The earlier a business is launched, the more profitable it will be.

10/12/2018

How a PCD Pharma Franchise is Different from a General Pharma Franchise?

In the franchise mode, a pharmaceutical company gives the authority to market the products to the resellers.

The franchise gets not only the business rights but the required support as well.

The model is an effective and efficient channel of distribution in India. All big and successful pharma companies have been using it for decades.

With the tremendous improvement in the infrastructure and facilities, the business model becomes furthermore lucrative for both parties.

In the pharma franchise business, two terms are prevalent; PCD Pharma Franchise and General Pharma Franchise.

PROMINENT DIFFERENCES BETWEEN THE PCD AND GENERAL PHARMA FRANCHISE
Before investing into the franchise business, an entrepreneur must know the rules of the business. How to decide whether PCD model is ideal for you or General franchise model?

Here are the noticeable differences between the two.

AREA OF SALES
PCD business is the smaller version of the general franchise. As compared to the latter, it covers a limited area. There can be several PCD franchises in a general franchise.

Thus, it is easy to understand that the PCD model is more beneficial and useful for small investors. They can start the business and make money easily.

For prominant entrepreneurs who have deep pockets, the general model is ideal.

INVESTMENT
Since the size of a PCD Franchise is small, it needs less money to launch the business as compared to the general model. It can be as low as 10000 bucks. On the other side, you need big money to start a universal franchise.

When the investment is less, the risk is also less.

The return on investment is corresponding to the investment and in the same proportion as well.

However, to begin with the PCD model first is easy. You can expand the business gradually after establishing the understanding of the market and business tactics.

EXPERIENCE
For a general franchise business, the experience and qualifications are more complex than the PCD franchise model.

Therefore, the PCD model seems to be more suitable for novice entrepreneurs.

PRODUCT LIST
In the PCD franchise, the products are limited whereas in the general franchise; the product list is quite extensive.

DISTRIBUTION CONTACTS OR CHANNELS
In the PCD model, the owners are directly linked to the retailers, clinics, and chemists. In the General Franchise model, the business owners have a grip over multiple sources of distribution.

Thus, the rules of the game are different in PCD and General franchise model.

10/12/2018

WHAT ARE SOFT GELATIN CAPSULES ?

Soft gelatin capsules consist of a filling, containing the dissolved or suspected active substance, and of a one-piece shell. Owing to the hermetic seal, the filling ingredients are protected against any harmful influence of the environment. Physical properties of solutions and suspensions, especially their homogeneity, allow the precision of dosage of active ingredients, rare in dry, orally received medications. In comparison with tablets and hard capsules, soft capsules require much less auxiliary substances, most of which are of herbal origin. The possibility to adjust the shell ingredients enables the adaptation of its parameters to specify requirements of storage conditions and especially to chemical as well as pharmacological properties of a medication.

The research on bioavailability of various medication forms has reportedly proved that the parameters of absorption and bioavailability of medications in the form of soft gelatine capsules are much better. It is mainly the result of one of the basic soft capsule features - the exact dispersion of a therapeutic substance in a liquid or semisolid medium. Owing to that, absorption of a medicament starts already at the moment of capsule disintegration in the alimentary tract, and is more effective thanks to the small size of suspended or dissolved particles of a medicament.

10/12/2018

Softgel capsules - the preferred dosage form
Consumer research surveys confirm that Softgels are the most popular delivery system. Softgel products have gained a 20% share of The U.S. cough and cold market and this has seen the launch of several major brand Softgel line extensions in the last few years. The success this has received shows that customers are prepared to pay more for fast acting innovative softgel products.

Softgels are easier to swallow than tablets

Liquid medicines can be offered as convenient solid unit doses

They are hygienic and tamper evident

They are seen as a very modern dosage form

The trend of self-medication has driven growth in the OTC market thereby providing new opportunities of product differentiation in Softgels

10/12/2018

Broad Injectables a Contract Manufacturing Pharmaceutical Company launched and initiated together a modern Lyophilizer for injection. WHO GMP quality assurance procedures guarantee a peak performance of all products. With the assistance of latest equipments, the automated and modern production process has been prepared. We offer a complete range of services with prompt and reliable assistance for all our customers. We manufacture an extensive spectrum of brand pharmaceutical formulation products in almost any form. Importers, distributors, and agents are always welcome to help us to introduce our products in their national markets.
Broad Injectables also provides attractive dossier licensing opportunities. Amongst the main activities, contract manufacturers of Injectables, Dry Liquid Injections, Ointments, Syrups, Capsules and Tablets are involved along with the production of Broad Injectables own commercial range. Being fully independent pharmaceutical formulation company, BROAD INJECTABLES offers flexible terms of trade and gives each customer a personal attention. Thanks to modern production line and WHO GMP standards, our products are of highest quality and yet reasonably priced.

Consequently, our large-scale production capacities, highly qualified production, and quality control staff, state of art WHO-GMP certified manufacturing facility combines to give a perfect environment for outsourcing or contract manufacturing pharmaceutical products. Kindly contact us for your requirements to enable us to give you our best rates. We offer our products on third party basis and under neutral label for export.

16/11/2018

How Injection Cures Your Back?

Various studies have shown that back pain and ESI are connected to each other as ESI is used to find the root cause of your back pain. Back pain has become a common phenomenon as there is an increasing change in the lifestyle of people. The main cause of back pain is a strain or an injury to the ligaments and the muscles that support the spine.

An Epidermal Steroid Injection is the one that is administered to patients who suffer from both, neck pain and back pain. An epidural space is defined as the space between the spinal cord and the inside portion of the spinal cord. The injection when administered to a patient who is suffering from back pain, travels through the whole length of spine. The medication moves freely in the spine, covering the nerve roots and lining of the facets joints.

The needle of the injection is inserted into the back portion of the patient. It is made sure that the injection needle has been inserted in the epidermal layer of the skin.

There are two categories of injections, one which provides you with a permanent relief and the other one that provides you a temporary one. The injections that help you to provide temporary relief are termed as therapeutic injections.

These injections are used with local anesthesia known as lidocaine. Another anesthesia, Bupivacaine is also used to relieve back pain. Cortisone is another common injection. It is injected with local anesthesia and is used to reduce the inflammation in the affected area of the patient.

There are three different ways by which you can administer to ESI. The first way, is known as the

caudal block. This process involves the use of a caudal block, which is placed through the sacral gap of the spinal cord. The injection is then placed into the epidural space. The advantage of this type of

injection method is that the probability of the puncturing of the dura is very less.

The other common method is termed as the translumbar process. In this method, a needle is placed between the two vertebrae of the back. In the third method, which is commonly called as the transforaminal process, the injection is administered around a very specific nerve root.

16/11/2018

Global Personalized Medicines Market

Personalized medicine is a concept that has the potential to transform medical interventions by providing effective and tailored therapies. The development of personalized medicine is a novel approach.
It includes the use of molecular analysis to achieve optimal medical outcome in management or diagnosis of patient’s disease. The main objective of personalized medicine is to identify most appropriate treatment option for patient population.

The market of personalized medicine is witnessing positive growth owing to the advancement in technologies coupled with introduction of new technologies by key players. For example, in June 2013, Natural Molecular Testing Corporation launched expanded cardiac personalized medicine based on Luminex Corporation’s xMAP technology. In addition, introduction of technologies like NanoVelcro chip devices and gene therapies by using pill for treating cancer will increase the customer base for personalized medicines and hence stimulates the market growth.

Furthermore, personalized medicines have increased the possibility of healthcare profits, safety of patients and improve the clinical results which will further drive the growth of the market of pharmacodiagnostics and personalized medicines. For example, personalized medicines offer cost-effective treatment and also eliminate overspending for the cancer treatment. This factor would ultimately attract more number of customers to use personalized medicines and hence drives the market growth. Moreover, various other factors like early diagnosis of diseases, high adverse reaction of prescription drugs, changing patient’s trend and patient compliance would also augment the market growth.

Furthermore, personalized medicines have major impact on small to medium sized enterprises (SMEs). It offers great business opportunities for these companies to develop their industrial boundaries across the globe. Thus, all the above mentioned factors would increase the use of personalized medicines by SMEs and hence further augments the market growth. However, implementation of personalized medicines in biomedical research and in clinical applications is still at a low pace which might restrict the growth of this market.

Geographically, North America dominates the global personalized medicines market. Advancement in technologies and increasing research activities on human DNA by various biotechnology companies in North America will drive the market growth. In addition, increasing incidence and prevalence of cancer and cardiovascular diseases in North America further drives the market growth. Europe is considered as the second largest market of personalized medicines.

The growth of personalized medicines market in Europe is mainly attributed to consistent efforts of private research institutes and government for the development of clinical application for cancer, heart diseases and neurodegenerative disorders. Asia-Pacific region is considered as an emerging market for personalized medicines owing to ability of personalized medicines to provide cost effective and safer treatment options.

The leading players competing in personalized medicines market are Bayer HealthCare Pharmaceuticals, Abbott Molecular, Inc., Celera Diagnostics, Hologic, Inc., Rosetta Genomics Ltd., Macrogen, Inc., IRIS Personalized Medicine, Bristol-Myers Squibb, Cepheid, Curagen Corp., Decode Genetics, Exagen Diagnostics, Dako Denmark A/S, Exact Sciences Corp. and others.

02/11/2018

Current Good Manufacturing Practices in Pharmaceutical Manufacturing

Current Good Manufacturing Practices (cGMP) are trailed by pharmaceutical and biotechnology organizations to guarantee that their things are made to particular necessities including character, quality, quality, and virtue. Great Manufacturing Practices are managed by the Food and Drug Administration (FDA).

There are various government regulations that identify with cGMP which, if not took after, can prompt criminal punishments. There are two particular regulations that identify with pharmaceutical producers, one for natural items, and a regulation that manages electronic records and electronic marks.

The Code of Federal Regulations (CFR) is a codification of the general and perpetual tenets of the national government. The CFR contains the complete and authority content of the regulations that are authorized by government orgs.

The CFR is separated into 50 titles that speak to expansive zones subject to Federal regulations. Each one title is isolated into sections that are doled out to different organizations issuing regulations relating to that expansive branch of knowledge. Every section is partitioned into parts covering particular administrative regions. Each one section or subpart is then partitioned into segments - the essential unit of the CFR. In some cases areas are subdivided further into sections or subsections. References relating to particular data in the CFR will normally be given at the segment level.

Current Good Manufacturing Practices and the Pharmaceutical Industry

The CFR's that identify with cGMP in the pharmaceutical and biotechnology organizations are:

21 CFR Part 210 - Current Good Manufacturing Practice in Manufacturing, Processing, Packing, or Holding of Drugs; General Part

21 CFR Part 211 - Current Good Manufacturing Practice for Finished Pharmaceuticals

21 CFR Part 600 - Biological Products: General

21 CFR Part 11 - Electronic Records; Electronic Signatures

When all is said in done, 21 CFR Part 210 oversees cGMP for the assembling, handling, bundling, or holding of medications. Section 210 incorporates the definitions that are utilized as a part of the regulations, for example, cluster, parcel, and so on.

The 21 CFR Part 211 is for cGMP for completed pharmaceuticals. For instance, a fluid pharmaceutical filtering through a plastic compartment would be secured by Part 210, however a pill breaking separated after it ships would likely be secured by Part 211.

21 CFR Part 600 is identified with Biological Products and contains key definitions, foundation guidelines, foundation investigation prerequisites and antagonistic experience reporting necessities.

21 CFR Part 11 contains the rules on electronic records and electronic marks. Section 11 characterizes the criteria under which electronic records and electronic marks are thought to be dependable, solid and comparable to paper records. Section 11 additionally applies to entries made to the FDA in electronic configuration.

Broad Injectables

26/12/2018

24/12/2018

10/12/2018

10/12/2018

10/12/2018

10/12/2018

10/12/2018

10/12/2018

10/12/2018

16/11/2018

16/11/2018

02/11/2018

Address

Website

Alerts

Contact The Business

Shortcuts

Share

Category